Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hypoxia × Temozolomide × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 37 Brain Neoplasms 16 Astrocytoma 16 Central Nervous System Neoplasms 9 Oligodendroglioma 8 Gliosarcoma 8 Melanoma 7 Glioma 7 Neoplasms 5 Recurrence 4 Neoplasm Metastasis 3 Diffuse Intrinsic Pontine Glioma 2 Choroid Plexus Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Sarcoma, Ewing 1 Sarcoma 1 Rhabdoid Tumor 1 Rare Diseases 1 Optic Nerve Glioma 1 Neurotoxicity Syndromes 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms, Neuroepithelial 1 Neoplasms, Connective and Soft Tissue 1 Neoplasms, Connective Tissue 1 Neoplasms, Bone Tissue 1 Neoplasms by Histologic Type 1 Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1 Lymphoma, Follicular 1

Interventions

Radiotherapy 2 Temozolomide 1 Nimorazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06477939 2024-06-27

THREE-GLEES

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting

Hypoxia, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡